Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1804-1810

  Donaldson, Meghan G ^a   Palermo, Lisa ^b   Ensrud, Kristine E ^c,d   Hochberg, Marc C ^e   Schousboe, John T ^c,f   Cummings, Steven R ^a  

^a California Pacific Medical Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f PARK NICOLLET INSTITUTE   (United States)

Author keywords

ALENDRONATE; BISPHOSPHONATE; FRACTURES; FRAX; TREATMENT

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL FRACTURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FEMORAL NECK BONE MINERAL DENSITY; FEMUR NECK; FRACTURE; FRAGILITY FRACTURE; FRAX SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POISSON DISTRIBUTION; RATING SCALE; RISK ASSESSMENT; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CONFIDENCE INTERVALS; FEMALE; FEMORAL NECK FRACTURES; FEMUR NECK; HUMANS; MIDDLE AGED; PLACEBOS; RISK ASSESSMENT; SPINAL FRACTURES;

EID: 84861304688     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1625     Document Type: Article

References (17)

1. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N., The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18 (8): 1033-46.
2. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E., FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19 (4): 385-97.
3. McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA., Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009; 20 (5): 811-7.
4. Kanis JA, Johansson H, Oden A, McCloskey EV., A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010; 47 (4): 729-35.
5. Kanis JA, Johansson H, Oden A, McCloskey EV., Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44 (6): 1049-54.
6. Kanis JA, Johansson H, Oden A, McCloskey EV., A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int. 2011 Aug; 22 (8): 2347-55. Erratum in: Osteoporos Int. 2011 Aug; 22(8) 2357-8.
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-82.
8. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR., Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3 (Suppl 3): S29-39.
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348 (9041): 1535-41.
10. Genant HK, Jergas M, van Kuijk C., Vertebral fracture in osteoporosis. San Francisco: Radiology Research and Educational Foundation; p. 450. 1995.
11. Melton LJ 3rd, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL., Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989; 129 (5): 1000-11.
12. McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA., Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007; 22 (1): 135-41.
13. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23 (12): 1923-34.
14. Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd., Updated fracture incidence rates for the US version of FRAX. Osteoporos Int. 2010; 21 (1): 25-33.
15. Kanis JA, Johansson H, Oden A, Dawson-Hughes B, Melton LJ 3rd, McCloskey EV., The effects of a FRAX revision for the USA. Osteoporos Int. 2010; 21 (1): 35-40.
16. Donaldson M, Cawthon P, Lui L, Schousboe J, Ensrud K, Taylor B, Cauley J, Hillier T, Black D, Bauer D, Cummings S;, Study of Osteoporotic Fractures. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009 Apr; 24 (4): 675-80.
17. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C., Use of oral corticosteroids in the United Kingdom. QJM. 2000; 93 (2): 105-11.